Presentation is loading. Please wait.

Presentation is loading. Please wait.

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel.

Similar presentations


Presentation on theme: "Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel."— Presentation transcript:

1 Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel Galicier, François Provôt, Claire Presne, Pascale Poullin, Guy Bonmarchand, Alain Wynckel, Ygal Benhamou, Philippe Vanhille, Aude Servais, Dominique Bordessoule, Jean-Philippe Coindre, Mohamed Hamidou, Jean-Paul Vernant, Agnès Veyradier, Paul Coppo, and Blood Volume 124(2): July 10, 2014 ©2014 by American Society of Hematology

2 Study flowchart. Study flowchart.
Miguel Hie et al. Blood 2014;124: ©2014 by American Society of Hematology

3 ADAMTS13 activity and CD19+ lymphocytes during follow-up.
ADAMTS13 activity and CD19+ lymphocytes during follow-up. (A) ADAMTS13 activity (%) and (B) CD19+ B lymphocytes at 0, 1, 3, 6, 9, 12, 18, and 24 months after the first preemptive rituximab course. Box plots represent quartiles, median, and range of laboratory measurements. The black line represents the variation of the mean over time. Circulating B cells were counted after mononuclear cell labeling with anti-CD19 antibodies. Cell-surface labeling was analyzed on a FACScan flow cytometer (Becton-Dickinson, San Jose, CA). Data were acquired from 104 cells in list mode and analyzed by using CellQuest software (Becton-Dickinson). Data are the mean ± standard deviation. Miguel Hie et al. Blood 2014;124: ©2014 by American Society of Hematology

4 Kaplan-Meier survival estimates of relapse-free survival.
Kaplan-Meier survival estimates of relapse-free survival. Survival of patients with TTP who received (n = 30; group 1) or did not receive (n = 18; group 2) preemptive rituximab was compared with the Kaplan-Meier estimator. Miguel Hie et al. Blood 2014;124: ©2014 by American Society of Hematology

5 Outcome in patients with TTP according to treatment.
Outcome in patients with TTP according to treatment. Patients of group 1 (n = 30) received preemptive rituximab; patients of group 2 (n = 18) did not. Miguel Hie et al. Blood 2014;124: ©2014 by American Society of Hematology


Download ppt "Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel."

Similar presentations


Ads by Google